Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of
Wenyan Liu1, Zhang Zhang, Zhi-Min Zhang
1School of Pharmacy, Jinan University; Guangzhou City Key Laboratory of Precision Chemical Drug Development; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, 601 Huangpu Avenue West, Guangzhou, 510632, China. pharmlzq@jnu.edu.cn.
Abstract:
Pancreatic cancer has been defined as one of the most complex and challenging cancers to treat, but very few valid therapeutic targets have been identified to date. To address this issue, a 61-compound library was readily created by Ugi reaction followed by phenotypic screening, leading to the discovery of two most potent inhibitors, P21 and P26, which significantly impair BxPC-3 pancreatic cancer cell survival. A series of interacting protein hits, such as GSTO1, FAM213A, RAB6A/6B/39A and USMG5, were subsequently identified by quantitative chemoproteomics studies. The main cellular target, GSTO1, was further validated as a novel pancreatic cancer therapeutic target.
Insights
Researchers identified novel therapeutic targets for pancreatic cancer by screening a compound library. Two potent inhibitors, P21 and P26, were discovered, with GSTO1 validated as a key target to impair cancer cell survival.
Area of Science:
- Oncology
- Medicinal Chemistry
- Proteomics
Background:
- Pancreatic cancer presents significant treatment challenges with limited validated therapeutic targets.
- Identifying novel strategies to combat this complex disease is crucial.
Purpose of the Study:
- To discover and validate new therapeutic targets for pancreatic cancer.
- To identify potent small molecules that inhibit pancreatic cancer cell survival.
Main Methods:
- A 61-compound library was synthesized using the Ugi reaction.
- Phenotypic screening was employed to identify active compounds.
- Quantitative chemoproteomics was used to identify protein targets.
- GSTO1 was validated as a key cellular target.
Main Results:
- Two potent inhibitors, P21 and P26, were discovered, significantly reducing BxPC-3 pancreatic cancer cell survival.
- Proteins including GSTO1, FAM213A, RAB6A/6B/39A, and USMG5 were identified as interacting partners.
- GSTO1 was confirmed as the primary cellular target.
Conclusions:
- GSTO1 represents a novel and validated therapeutic target for pancreatic cancer.
- The identified inhibitors demonstrate potential for further drug development against pancreatic cancer.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:02Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
Published on: December 19, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Thermodynamics: Chemical Potential and Activity
The thermodynamic equilibrium constant is more accurately defined in terms of activity rather than concentration.
Gene Therapy
Activation and Inactivation of G Proteins
Acid–Base Equilibria: Activity-Based Definition of pH
In solutions of very low ionic strength—for example, pure water—the...